3 active not recruiting, 3 completed, 2 terminated, 1 recruiting. 10 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Active not recruiting 3, Completed 3, Terminated 2, Recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Malignant Neoplasm of Breast: new trials by email Literature Review of Malignant Neoplasm of Breast trials Research Report on Malignant Neoplasm of Breast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer HTR2 T Cells - Breast Cancer, Tumor, Breast | Phase 1 | Recruiting | Baylor College of Medicine | 27 | 2026-08-03 | 2026-09-24 |
| A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer Two Component Product CLBR001 + ABBV-461 - Breast Cancer Metastatic, Locally Advanced Breast Cancer (LABC) | Phase 1 | Terminated | Calibr, a division of Scripps Research | 10 | 2025-04-17 | 2026-05-28 |
| Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT Pembrolizumab, Clostridium Novyi-NT, Doxycycline - Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs | Phase 1 | Completed | M.D. Anderson Cancer Center | 18 | 2018-07-10 | 2026-11-03 |
| Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer DS-8201a - Malignant Neoplasm of Breast | Phase 1 | Completed | Daiichi Sankyo Co., Ltd. | 51 | 2017-12-26 | 2022-04-12 |
| Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer Trastuzumab, Ibrutinib 560 mg, Ibrutinib 840 mg - Breast Neoplasms, Malignant Neoplasm of Breast | Phase 1 / Phase 2 | Active not recruiting | US Oncology Research | 34 | 2017-11-29 | 2024-12-06 |
| Selumetinib and Olaparib in Solid Tumors Selumetinib, Olaparib - Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 90 | 2017-08-04 | 2026-10-13 |
| Lenvatinib and Capecitabine in Patients With Advanced Malignancies Lenvatinib, Capecitabine - Advanced Cancer, Malignant Neoplasm of Breast | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2016-12-01 | 2017-06-26 | |
| Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy Mammaglobin-A DNA Vaccine, Optional biopsy - Breast Cancer, Breast Carcinoma | Phase 1 | Active not recruiting | Washington University School of Medicine | 27 | 2015-01-07 | 2026-04-21 |
| Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors Alisertib, Pazopanib - Malignant Neoplasm of Breast, CNS Malignancy | Phase 1 | Completed | University of Illinois at Chicago | 28 | 2013-08-14 | 2019-07-22 |
| A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer Lapatinib, Caelyx - HER-2 Positive Breast Cancer, Malignant Neoplasm of Breast | Phase 1 | Terminated | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 11 | 2009-12-01 | 2016-02-02 |
Breast Neoplasms (10) · Urologic Neoplasms (2) · Central Nervous System Neoplasms (1) · Gastrointestinal Neoplasms (1) · Head and Neck Neoplasms (1) · Mammary Neoplasms, Animal (1) · Melanoma (1) · Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Breast Diseases (10) · Neoplasms by Site (10) · Skin Diseases (10) · Skin and Connective Tissue Diseases (10) · Neoplasms (9) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Male Urogenital Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Urologic Diseases (2) · Animal Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1)
AZD 6244 (1) · Capecitabine (1) · Doxycycline (1) · Lapatinib (1) · MLN 8237 (1) · Trastuzumab (1) · ibrutinib (1) · lenvatinib (1) · liposomal doxorubicin (1) · olaparib (1) · pazopanib (1) · pembrolizumab (1) · trastuzumab deruxtecan (1)
M.D. Anderson Cancer Center (3) · Baylor College of Medicine (1) · Calibr, a division of Scripps Research (1) · Daiichi Sankyo Co., Ltd. (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · US Oncology Research (1) · University of Illinois at Chicago (1) · Washington University School of Medicine (1)
United States (7) · Italy (1) · Japan (1)
Arkadiusz Z. Dudek, M.D. (1) · David S. Hong, MD (1) · Dino Amadori, MD (1) · Joyce O'Shaughnessy, MD (1) · Natalie Chen, MD (1) · Sarina Piha-Paul, MD (1) · Sarina Piha-Paul, MD, PHD (1) · Shannon Westin, MD (1) · William Gillanders, M.D. (1)
PMID 28341957, PMID 30973373, PMID 32379297, PMID 36164935, PMID 42504645
2009 (1)